10-Q: SANUWAVE Health Reports 53% Revenue Growth in Second Quarter, Achieves Net Income

Sentiment:

Quarterly Report 12 August 2024 4:08 PM

SANUWAVE Health, Inc. saw a 53% increase in revenue and achieved net income for the second quarter of 2024, driven by strong sales of its UltraMIST system.

Capital raiseThe company's ability to continue as a going concern is dependent on raising additional capital.Management plans may include obtaining additional capital in 2024 through various means, including the conversion of outstanding warrants, issuance of common or preferred stock, or secured or unsecured debt.The company could obtain additional capital through the conversion of outstanding warrants, issuance of common or preferred stock, securities convertible into common stock, or secured or unsecured debt.

Better than expectedThe company's revenue growth of 53% exceeded expectations.The company achieved net income for the quarter, a significant improvement from previous losses.Operating income showed a substantial positive trend, indicating improved profitability.

Summary

SANUWAVE Health, Inc. reported a significant 53% increase in revenue for both the three and six months ended June 30, 2024, compared to the same periods in 2023.
Revenue for the three months ended June 30, 2024, reached $7.2 million, up from $4.7 million in 2023.
For the six months ended June 30, 2024, revenue totaled $12.9 million, compared to $8.5 million in the prior year.
The company achieved net income of $6.6 million, or $0.01 per share, for the three months ended June 30, 2024, a significant turnaround from a net loss of $7.3 million in the same period of 2023.
Net income for the six months ended June 30, 2024, was $2.0 million, or $0.00 per share, compared to a net loss of $20.4 million in the same period of 2023.
The improved financial performance was primarily due to increased sales of the UltraMIST system, a gain on debt extinguishment, and a decrease in the change of fair value of derivative liabilities.
Operating income for the three months ended June 30, 2024, was $2.0 million, a $1.1 million improvement year-over-year.
Operating income for the six months ended June 30, 2024, was $0.9 million, a $2.0 million improvement year-over-year.
The company terminated its merger agreement with SEPA on June 25, 2024, and is exploring alternative options for uplisting and strengthening its financial position.

Sentiment

Score: 7

Explanation: The document shows strong revenue growth and a shift to profitability, which is very positive. However, the company's debt issues, material weaknesses in internal controls, and dependence on future capital raises temper the overall sentiment. The termination of the merger agreement is also a negative factor.

Positives

The company experienced substantial revenue growth of 53% year-over-year for both the three and six month periods.
SANUWAVE achieved net income for both the three and six months ended June 30, 2024, a significant improvement from net losses in the same periods of 2023.
Operating income showed a strong positive trend, increasing by $1.1 million and $2.0 million for the three and six month periods respectively.
The company recognized a significant gain on the extinguishment of debt, positively impacting the bottom line.
A one-time payment of $2.5 million was received related to a patent license agreement, boosting other income.

Negatives

The company has a history of recurring losses from operations.
The company is in default on its senior secured debt.
The company's ability to continue as a going concern is dependent on raising additional capital.
The company has identified material weaknesses in its internal control over financial reporting.
The company terminated its merger agreement with SEPA, incurring $0.5 million in deferred offering costs.

Risks

The company's recurring losses from operations and default on notes payable raise substantial doubt about its ability to continue as a going concern.
The company is dependent on future issuances of equity or other financing to fund ongoing operations, which may result in significant dilution to existing stockholders.
The company has identified material weaknesses in its internal control over financial reporting, which could lead to misstatements in financial reports.
The company relies on single suppliers for most of its product component materials, and the loss of any of these suppliers could disrupt production.
The company is involved in various legal proceedings, the outcomes of which are unpredictable and could have a material adverse effect on the business.

Future Outlook

The company plans to explore alternative options for uplisting to a national exchange and strengthen its financial position. Management plans may include obtaining additional capital in 2024 through various means, including the conversion of outstanding warrants, issuance of common or preferred stock, or secured or unsecured debt.

Management Comments

Management is committed to remediating the material weaknesses in internal control over financial reporting.
Management believes that the company's market valuation should be commensurate with the fundamentals of the business.
Management plans to continue to perform additional analyses and other procedures to ensure that the consolidated financial statements are prepared in accordance with U.S. GAAP.

Industry Context

The medical device industry is competitive, and SANUWAVE's performance is being driven by increased sales of its UltraMIST system. The company's focus on noninvasive and biological response activating medical systems aligns with trends in regenerative medicine. The company's financial performance is being impacted by its debt obligations and the need for additional capital.

Comparison to Industry Standards

While specific competitor data is not provided, the 53% revenue growth is a strong indicator of market traction for SANUWAVE's products.
The company's shift to net income from a net loss is a positive sign, but the ongoing debt issues and material weaknesses in internal controls are areas of concern.
The company's reliance on single suppliers is a common risk in the medical device industry, but it needs to be mitigated.
The company's need for additional capital is not uncommon for growth-stage medical device companies, but the terms of any financing will be critical.

Legal Proceedings

The company settled a dispute with Celularity in June 2024 for $2.2 million, resulting in a gain on extinguishment of debt of $5.3 million.

Related Party Transactions

The company entered into a $0.5 million promissory note with a related party in June 2024.

Stakeholder Impact

Shareholders will be impacted by the potential dilution from future capital raises.
Employees may be affected by the company's financial instability and potential restructuring.
Customers may be impacted by potential disruptions in production due to supply chain risks.
Creditors are at risk due to the company's default on its senior secured debt.

Next Steps

The company will explore alternative options for uplisting to a national exchange.
The company will seek to strengthen its financial position.
The company will continue to remediate material weaknesses in internal control over financial reporting.
The company will explore options for raising additional capital.

Key Dates

Date	Description
2020-08-31	Reference date for Senior Secured Promissory Notes Payable.
2022-02-28	Date of Second Amendment to Note and Warrant Purchase and Security Agreement.
2022-08-31	Reference date for Securities Purchase Agreement and Future Advance Convertible Promissory Notes.
2022-11-03	Reference date for Securities Purchase Agreement and Future Advance Convertible Promissory Notes.
2023-01-01	Start date for various financial reporting periods.
2023-04-01	Start date for various financial reporting periods.
2023-05-31	Reference date for Securities Purchase Agreement and Future Advance Convertible Promissory Notes.
2023-06-30	End date for the quarterly and six-month financial reporting periods.
2023-07-01	Reference date for Asset-Backed Secured Promissory Notes.
2023-07-31	Reference date for Asset-Backed Secured Promissory Notes.
2023-08-23	Date of the Merger Agreement with SEPA.
2023-12-31	End date for the annual financial reporting period.
2024-01-01	Start date for various financial reporting periods.
2024-01-21	Maturity date of Asset-Backed Secured Promissory Notes and issuance of Convertible Notes.
2024-01-31	Reference date for Securities Purchase Agreement and Future Advance Convertible Promissory Notes.
2024-02-27	Date of Amendment Number one to Agreement and Plan of Merger.
2024-02-29	Reference date for SEPAcquisitionCorpMember.
2024-03-21	Filing date of the 2023 Annual Report on Form 10-K.
2024-04-01	Start date for various financial reporting periods.
2024-04-25	Date of Amendment Number Two to Agreement and Plan of Merger.
2024-05-28	Date of Amendment Number Three to Agreement and Plan of Merger.
2024-06-01	Reference date for CelularityMember.
2024-06-25	Date of termination of the Merger Agreement with SEPA.
2024-06-30	End date for the quarterly and six-month financial reporting periods.
2024-07-15	Date of the Sixth Amendment to Note and Warrant Purchase and Security Agreement.
2024-08-07	Date of approval of proposals related to reverse stock split and equity incentive plan.
2024-08-08	Date of outstanding share count.
2024-08-12	Date of report filing.

Keywords

UltraMIST, revenue growth, net income, financial results, debt, internal controls, medical devices, warrants, promissory notes, capital raise

Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.